Patents by Inventor Robert Lazarus

Robert Lazarus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating cardiovascular disease
    Patent number: 11034725
    Abstract: The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: June 15, 2021
    Assignee: Genentech, Inc.
    Inventors: Maureen Beresini, Daniel Burdick, Charles Eigenbrot, Jr., Daniel Kirchhofer, Robert Lazarus, Wei Li, John Quinn, Nicholas Skelton, Mark Ultsch, Yingnan Zhang
  • Compositions and methods for treating cardiovascular disease
    Patent number: 10787484
    Abstract: The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: September 29, 2020
    Assignee: Genentech, Inc.
    Inventors: Maureen Beresini, Daniel Burdick, Charles Eigenbrot, Jr., Daniel Kirchhofer, Robert Lazarus, Wei Li, John Quinn, Nicholas Skelton, Mark Ultsch, Yingnan Zhang
  • COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE
    Publication number: 20200283478
    Abstract: The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.
    Type: Application
    Filed: May 26, 2020
    Publication date: September 10, 2020
    Applicant: Genentech, Inc.
    Inventors: Maureen Beresini, Daniel Burdick, Charles Eigenbrot, Jr., Daniel Kirchhofer, Robert Lazarus, Wei Li, John Quinn, Nicholas Skelton, Mark Ultsch, Yingnan Zhang
  • COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE
    Publication number: 20190177366
    Abstract: The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 13, 2019
    Applicant: Genentech, Inc.
    Inventors: Maureen Beresini, Daniel Burdick, Charles Eigenbrot, JR., Daniel Kirchhofer, Robert Lazarus, Wei Li, John Quinn, Nicholas Skelton, Mark Ultsch, Yingnan Zhang
  • Method for generating potent dendritic cells
    Patent number: 9273284
    Abstract: Highly potent dendritic cells are generated in vivo or ex vivo by exposing precursor cells to an effective dose of IL-32.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: March 1, 2016
    Assignee: The Regents of the University of California
    Inventors: Robert Lazarus Modlin, Mirjam Schenk
  • Method for Generating Potent Dendritic Cells
    Publication number: 20140056845
    Abstract: Highly potent dendritic cells are generated in vivo or ex vivo by exposing precursor cells to an effective dose of IL-32.
    Type: Application
    Filed: April 16, 2012
    Publication date: February 27, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Robert Lazarus Modlin, Mirjam Schenk
  • METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
    Publication number: 20070129301
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: October 2, 2006
    Publication date: June 7, 2007
    Inventors: Daniel Kirchhofer, Robert Lazarus, Xiaoyi Yao
  • HGF beta chain variants
    Publication number: 20060293235
    Abstract: The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.
    Type: Application
    Filed: April 17, 2006
    Publication date: December 28, 2006
    Inventors: Daniel Kirchhofer, Robert Lazarus, Christian Wiesmann
  • Methods and compositions for modulating HGF/Met
    Publication number: 20060035278
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: June 4, 2004
    Publication date: February 16, 2006
    Inventors: Daniel Kirchhofer, Robert Lazarus, Xiaoyi Yao
  • Factor VIIa variants
    Publication number: 20060019893
    Abstract: Novel compounds are provided which modulate a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention are variants of Factor VIIa (FVIIa). Pharmaceutical compositions are also provided which comprise the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Application
    Filed: June 23, 2005
    Publication date: January 26, 2006
    Applicant: Genentech, Inc.
    Inventors: Henry Maun, Charles Eigenbrot, Robert Lazarus
  • Crystal structure of the hepatocyte growth factor and methods of use
    Publication number: 20060003931
    Abstract: The disclosure provides a crystal and crystal structure of the Hepatocyte Growth Factor Beta (HGF ?) Chain, as well as use of the crystal structure in the design, identification, and selection of modulators of HGF or Met activity.
    Type: Application
    Filed: May 6, 2005
    Publication date: January 5, 2006
    Applicant: Genentech, Inc.
    Inventors: Charles Eigenbrot, Daniel Kirchhofer, Robert Lazarus
  • Human DNase I hyperactive variants
    Publication number: 20050170365
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive-variants of human DNase I.
    Type: Application
    Filed: May 3, 2004
    Publication date: August 4, 2005
    Inventors: Robert Lazarus, Clark Pan
  • Methods and compositions for modulating HGF/Met
    Publication number: 20050037431
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: June 4, 2004
    Publication date: February 17, 2005
    Inventors: Daniel Kirchhofer, Robert Lazarus, Xiaoyi Yao